Status:
UNKNOWN
New Time Clock for ST-elevation MI Based on Biochemical Myocardial Infarction Onset Time
Lead Sponsor:
Tabba Heart Institute
Conditions:
Mi Q Wave
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Brief Summary
ST segment elevation myocardial infarction (STEMI) is one of the leading causes of death across the world and immediate treatment with either thrombolytics or percutaneous coronary intervention (PCI) ...
Detailed Description
ST segment elevation myocardial infarction (STEMI) is one of the leading causes of death across the world (1) and immediate treatment with either thrombolytics or percutaneous coronary intervention (P...
Eligibility Criteria
Inclusion
- All adult males and females coming to the ER of the hospital with acute STEMI
- Both initial and follow up patients will be included
- Patients coming within the time frame of reperfusion therapy with primary PCI i.e. within 24 hours of patient reported onset of symptoms.
Exclusion
- Patients receiving thrombolytic therapy as first mode of therapy outside hospital or inside the ER.
- Moderate to severe renal disease (Creatinine clearance\<40)
- Recent acute coronary syndrome (ACS) within last 14 days with troponin rise
- Post-CABG or PCI patients within 14 days of procedure
- Patients with cardiogenic shock and cardiac arrest, due to expected high mortality since these patients will not be available for follow up
- Patients incapable of providing reliable history due to impaired memory or other reasons
Key Trial Info
Start Date :
July 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04389814
Start Date
July 15 2019
End Date
August 30 2020
Last Update
May 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tabba Heart Institute
Karachi, Sindh, Pakistan, 75950